Cite
MLA Citation
Eric Angevin et al.. “A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.” European journal of cancer, vol. 87, 2017, pp. 131–139. http://access.bl.uk/ark:/81055/vdc_100054256752.0x000033